Resumen
Management of anticoagulant therapy for the treatment of venous thromboembolism (vte) in cancer patients is complex because of an increased risk of recurrent vte and major bleeding complications in those patients relative to the general population. Subgroups of patients with cancer also show variation in their risk for recurrent vte and adverse bleeding events. Accordingly, a committee of 10 Canadian clinical experts developed the consensus risk-stratification treatment algorithm presented here to provide guidance on tailoring anticoagulant treatment choices for the acute and extended treatment of symptomatic and incidental vte, to prevent recurrent vte, and to minimize the bleeding risk in patients with cancer. During a 1-day live meeting, a systematic review of the literature was performed, and a draft treatment algorithm was developed. The treatment algorithm was refined through the use of a Web-based platform and a series of online teleconferences. Clinicians using this treatment algorithm should consider the bleeding risk, the type of cancer, and the potential for drug–drug interactions in addition to informed patient preference in determining the most appropriate treatment for patients with cancer-associated thrombosis. Anticoagulant therapy should be regularly reassessed as the patient’s cancer status and management change over time.
| Idioma original | English |
|---|---|
| Páginas (desde-hasta) | 329-337 |
| Número de páginas | 9 |
| Publicación | Current Oncology |
| Volumen | 25 |
| N.º | 5 |
| DOI | |
| Estado | Published - oct. 2018 |
Nota bibliográfica
Funding Information:We have read and understood Current Oncology’s policy on disclosing conflicts of interest, and we declare the following interests: MCa has received research funding from Bristol–Myers Squibb, Leo Pharma, and Pfizer, and honoraria from Bayer, Bristol–Myers Squibb/Pfizer, Leo Pharma, Sanofi, Pfizer, and Servier; AYYL has received research funding from Bristol–Myers Squibb and consultancy fees or honoraria from Bayer, Leo Pharma, Pfizer, and Servier; VT has received research funding from Pfizer and Sanofi and honoraria from Bayer, Bristol–Myers Squibb, Leo Phama, Pfizer, Sanofi, and Servier; CW has received honoraria from Bristol–Myers Squibb/Pfizer, Leo Pharma, and Pfizer, and has served as a local principal investigator for studies that have received funding or support from Bayer, Bristol–Myers Squibb/Pfizer, and Daiichi Sankyo; MCr has received grant support, consulting fees, and drugs supplied for a study from Bayer; advisory board fees from Octapharma, Shionogi, and Bristol–Myers Squibb/Pfizer; fees for preparation and presentation of educational materials from Pfizer, Alexion, and Boehringer Ingelheim; advisory board fees, fees for serving on a steering committee, and travel support from Portola; and grant support from Leo Pharma; GLG has received grants from Portola Pharmaceuticals, was a co-investigator for trials conducted by Boehringer Ingelheim, Pfizer, GlaxoSmithKline, Bristol–Myers Squibb, Leo Pharma, Daiichi Sankyo, and Bayer, and has received honoraria from Bayer, Pfizer, GlaxoSmithKline, Leo Pharma, Sanofi, and bioMerieux outside the submitted work. The remaining authors have no conflicts to disclose.
Publisher Copyright:
© 2018 Multimed Inc.
ASJC Scopus Subject Areas
- Oncology
ODS de las Naciones Unidas
Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible
